Outpacing conventional drug discovery to unlock the full potential of high value targets

Chemoproteomics is providing a new path to a universe of previously inaccessible therapeutic targets – yet drug discovery has remained inefficient, with patients waiting for new hope. Now, Jnana scientists are unlocking the full potential of chemoproteomics to uncover unique binding sites on highly validated protein targets and accelerate the discovery of new molecules that can change the course of disease.

Patients today are in need of new medicines. Jnana’s RAPID platform allows us to systematically develop small molecule medicines for any target class with unmatched speed and efficiency. Together, we are advancing first- and best-in-class therapies to treat phenylketonuria (PKU) and a broad range of immune-mediated diseases.

Drug discovery is not for the faint of heart. Breakthroughs are achieved through perseverance, wisdom gained through experience, and possibility fueled by collaboration and the power of ideas.